You may be eligible for the Pulmozyme Co-pay Assistance Program.

With the Pulmozyme Co-pay Assistance Program, eligible patients with commercial insurance could pay as little as $30 a month for Pulmozyme. Co-pay assistance is provided up to $10,000 for a 12-month period.

The remainder of the co-pay or co-insurance is covered up to $10,000 a year
There is no income requirement

Apply online

You may be eligible if you:

Have a valid prescription for Pulmozyme for an FDA-approved use
Reside in the United States or U.S. Territories
Are over the age of 18, or have a Legally Authorized Person over the age of 18 to manage the program
Have commercial (private or non-governmental) insurance. This includes plans available through state and federal health insurance exchanges
Are not currently receiving Pulmozyme from the Genentech Patient Foundation
Are not currently receiving assistance from any other charitable organization for any of your out-of-pocket costs that are covered by the Pulmozyme Co-pay Assistance Program
Are not using a state or federal healthcare plan to pay for their medication. This includes, but is not limited to, Medicare, Medicaid and TRICARE

Under the program, the patient will pay a co-pay. After reaching the maximum program benefit, the patient will be responsible for all out-of-pocket expenses. All participants are responsible for reporting the receipt of all program benefits as required by any insurer or by law. No party may seek reimbursement for all or any part of the benefit received through this Program. The program is only valid in the United States and U.S. Territories. This program is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. The patient, guardian, prescriber, hospital and any other person using the program agree not to seek reimbursement for all or any part of the benefit received by the patient through the offer of this program. Genentech reserves the right to rescind, revoke or amend the program without notice at any time. Additional terms and conditions apply.

View full TERMS AND CONDITIONS

Questions? Contact Pulmozyme Support

Call 877-794-8723 (Mon.–Fri., 6AM–5PM PST, except major holidays)

We are open from 6AM-5PM PST, Mon. through Fri., except for the following holidays:
- New Year's Day
- Memorial Day
- Independence Day
- Labor Day
- Thanksgiving Holiday (Thursday and Friday)
- Christmas Day

Back to Pulmozyme Financial Support Tool

Indication & Usage

Pulmozyme (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

Pediatric Use

The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of Pulmozyme should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection.

The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to <10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Pulmozyme Prescribing Information for additional Important Safety Information. If you have questions, please discuss them with your CF Care Team.

You may be eligible for the Pulmozyme Co-pay Assistance Program.

Questions? Contact Pulmozyme Support

Important Safety Information & Indications

Indication & Usage

Important Safety Information

Pediatric Use